Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Zalevsky Jonathan, holds the title of Chief R&D Officer at NEKTAR THERAPEUTICS.
On 2026-11-17, the insider transacted 192 shares.The shares were transacted at a weighted average price of $35.85 per share, resulting in a total market-relevant value of $7K.
Zalevsky Jonathan (Chief R&D Officer) sold $7K of $NKTR
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.